The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by https://U.S. News & World Report for more than 30 years.
In compliance with applicable State regulatory authorities, vaccination for COVID-19 and Influenza (flu) is mandatory for all MSK staff who do not work 100% remotely (including new hires ). Staff are considered fully vaccinated upon completion of a primary vaccination series for COVID-19 Exceptions from the COVID-19 vaccine requirement are permitted for those who request and receive an approved medical, religious, or fully remote exemption. Requests for exemption can take up to two weeks to review. Vaccination or an approved medical exemption is required to start work.
The Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Cancer Center seeks to recruit an exceptional academic physician to serve as the Chief of the Thoracic Oncology Service. The Thoracic Oncology Service is one of ten services in the Division of Solid Tumor Oncology that includes, in addition to Thoracic Oncology, Breast Oncology, Genitourinary Oncology, Clinical Genetics, Head and Neck Oncology, Early Oncology Drug Development, Melanoma, Sarcoma, Gastrointestinal Oncology and Gynecologic Medical Oncology.
The Thoracic Oncology Service is composed of twenty-five academic faculty who deliver care across New York City and surrounding areas including Long Island, New Jersey, and Westchester County. The faculty consist of experts in treatment of molecularly defined subsets of small cell and non-small cell lung cancer, mesothelioma, thymic cancer, and neuroendocrine lung tumors. The service on average delivers over 27,000 outpatient visits with 2,200 new patients per year. The Thoracic Oncology Program faculty lead a large portfolio of research projects that span the entire research continuum and include faculty based in both wet and dry laboratories. Our highly productive research programs lead over eighty-four clinical trials with major contribution to the FDA approvals of adagrasib, sotorasib, mobocertinib, trastuzumab deruxtecan, and selpercatinib. This work is supported by $325 million in funding in the last 5 years, including $257 million across eighty-eight industrial contracts and sponsored research agreements, $52 million across twenty federal grants, and $16 million in external funding. Faculty in the Thoracic Oncology Program collaborate closely with physicians and physician scientists from across all MSK’s Basic and Clinical Departments. Partnerships with Thoracic Surgery, Radiation Oncology, Radiology, Pathology, Pulmonary and Interventional Pulmonology are extremely strong and facilitate large ambitious research projects.
The new Service Chief will report to the Division Head, Solid Tumor Oncology, Dr. Luis Diaz and will have programmatic oversight and operational responsibility for the Thoracic Oncology Service and all its faculty. The Chief will set the strategic, research, clinical and operational priorities for the Service. S/he will champion clinical operations, talent acquisition and retention, research, philanthropy, professional development, mentorship, and teaching. S/he will partner closely with MSK’s senior leadership to set the institutional vision particularly given that thoracic malignancies remain the number one cause of death worldwide. The ideal candidate is highly collegial and experienced in building strong teams that can execute high impact research projects, train the next generation of thoracic oncologists and deliver exceptional clinical care.
The ideal candidate will have international recognition as a thought leader in thoracic oncology, and a history of conducting high impact studies in either clinical, translational, laboratory-based, or population science.
Interested candidates should apply by sending a brief statement of prior experience, research interests and a CV to Yelena Janjigian, MD janjigiy@https://mskcc.org and cc Valentina Salkow, Manager, Academic Recruitment, salkowv@https://mskcc.org.
Expected salary range is $335,000-$655,000 for this role.
Physician compensation is based on multiple variables. This range represents annual salary only and does not include supplemental performance-based pay or any one-time payments that eligible candidates may be offered at the time of hire.